ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INMD / forecast
CBLL (43) CNMD (62) CV (43) TMDX (61) ⌘ Pro Terminal →

InMode Ltd. (INMD) 12-Month Stock Forecast & Price Target Cone

$13.70 +3.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.76

InMode Ltd. (INMD) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $759.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, InMode Ltd. (NASDAQ: INMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $13.70 (+3.63% 1D, market cap $759.9M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, INMD ranks #192 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INMD compare to CBLL and CNMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.32B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INMD?
▼

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (78.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.76 (+0.46%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 22.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-
Cash (15)Whales (3)SEC (16)Macro (8)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
$18 Bull$14 Base$11 Bear
📬 FREE INMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMD)Realized 20D OHLCV Swing Band: ±3.2%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY INMD SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 9.20 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 22.7% FCF Margin ($84.3M FCF) & 78.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$14.31-1.2% Next Q
Q2 (-2Q)
62
Grade C+$14.14-4% Next Q
Q3 (-1Q)
60
Grade C$13.58+0.9% Next Q
Current
57
Grade D+$13.70-0.2% Hist 90D α
Trajectory: C+ (65) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, INMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 76.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.31) or 200D SMA ($14.32) invalidates the momentum regime and cuts Target Base ($13.64) toward Bear Floor ($10.64).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 57%NO 43%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your INMD Position Size: $10,000

Shares at $13.70: 729.9 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $10.64
$7,766
$-2,234 (-22.3%)
12M Consensus BaseTarget $13.64
$9,956
$-44 (-0.4%)
12M Bull Case BreakoutTarget $17.50
$12,774
+$2,774 (+27.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1669%B
JP MorganUS Large-Cap ResearchSELL$1258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INMD)

  • ✓Walkthrough of INMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.26%📐 HORIZONTAL RANGE
2026-11-03O $13.51H $13.70L $13.22C $13.70VOL 439.9K
RES: $14.55SUP: $13.19SMA50: $14.31SMA200: $14.32
$15.84$15.12$14.41$13.69$12.97RES $14.55SUP $13.19$13.702026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMD Butterfly Map → + Track INMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-8.3%/yr Implied 5Y Growth

vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMD)

Health Care Rank #192 of 1015 ⚔️ CBLL vs INMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMD vs. CBLL, CNMD, CV, TMDX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, InMode Ltd. (INMD) ranks #192 by composite RQD confidence (57/100, grade D+) and #388 by equity capitalization ($759.9M). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with INMD at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INMD ACTIVE
InMode Ltd.
D+ 57/100 — 78.5% 17.7% +3.63% $759.9M Benchmark Subject
CBLL
CeriBell Inc.
D- 43/100 — 87.9% -35.0% +1.43% $1.02B /cbll-vs-inmd →
CNMD
CONMED Corporation
C 62/100 28.9x 54.6% 7.8% +5.19% $1.32B /cnmd-vs-inmd →
CV
CapsoVision Inc.
D- 43/100 — 52.9% -35.0% -1.46% $363.3M /cv-vs-inmd →
TMDX
TransMedics Group Inc.
C- 61/100 12.2x 59.9% 18.1% +1.03% $2.29B /tmdx-vs-inmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001742692 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InMode Ltd. (INMD) reported GAAP revenue of $370.5M (-6.2% vs. FY2024 revenue of $394.8M , and -24.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $85.3M, and free cash flow of $84.3M (-36.1% YoY). On the balance sheet, INMD closed FY2025 with $766.4M in total assets against $0 in total debt (Altman Z-Score: 9.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $370.5M $0 $85.3M $84.3M $766.4M —
FY2024 (FY) 2024-12-31 $394.8M $0 $132.7M $132.0M $785.7M —
FY2023 (FY) 2023-12-31 $492.0M $197.9M $176.8M $176.8M — —

3. INMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, InMode Ltd. (NASDAQ: INMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $13.70 (+3.63% 1D, market cap $759.9M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, INMD ranks #192 in composite RQD confidence.

How does INMD compare to CBLL and CNMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.32B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INMD?

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (78.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.70 (+3.63% on volume of 1,114,417 shares), positioning the stock -4.26% below its 50-day simple moving average ($14.31) and -4.33% below its 200-day simple moving average ($14.32). Across its 52-week range of $12.72 to $16.67, INMD sits at the 24.8% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±3.2% ($13.26 to $14.14).

Direct Sub-Reports: INMD RQD Cockpit INMD 12M Forecast INMD Earnings & Move INMD Dividends & DRIP INMD Insiders & 13F INMD Whale Options INMD Profit Sankey INMD News & Why
ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

INMD — InMode Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

InMode Ltd. (INMD) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $13.70 (+3.63% 1D, market capitalization $759.9M).

  • Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 17.7%, gross margin of 78.5%, operating margin of 23.0%, and free cash flow yield of 10.85%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

InMode Ltd. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the market data, the company reports a gross margin of 78.5% and an operating margin of 23%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), InMode Ltd. (INMD) reported $370.5M in annual revenue (up from $394.8M in FY2024, -6.2% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($492.0M revenue, $197.9M net income) through FY2025, INMD scaled operating cash flow to $85.3M and free cash flow to $84.3M, backed by $766.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 57/100): Strong cash generator (78.5% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $12.72 – $16.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation and 5.5x EV/EBITDA against 23.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependency mapping. Sector and industry classification (Health Care; Electromedical & Electrotherapeutic Apparatus) is the only sector-level information provided. A prospective investor should watch the outcome of the Steel Partners offer and the Q3 2026 results on November 11, 2026, as these items are the only dated events in the source data that could reprice the equity.

  • Key Question #1: Can INMD sustain or expand its 23.0% operating margin and 17.7% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $370.5M and free cash flow of $84.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InMode Ltd. (INMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INMD Bull vs. Bear Conversation Board — What's Your Call at $13.70?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $15.86 (+20.0%)
📌 Pinned Debate

A 17.7% ROIC and 10.85% FCF yield indicate strong cash generation, backed by a pending $16.75 per share all-cash offer from Steel Partn

Long INMD at $13.22 targeting $15.86. A 17.7% ROIC and 10.85% FCF yield indicate strong cash generation, backed by a pending $16.75 per share all-cash offer from Steel Partners.. Institutional whale score is 3/20 and the risk/reward vs. the $12.72 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (78.5%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $10.18 (-23.0%)
Spot @ $13.22

Revenue fell from $492.0M in FY 2023 to $370.5M in FY 2025 while net margin is 0% and the whale 13F flow pillar scored only 4 of 20.

Fading this rally in INMD at $13.22. Revenue fell from $492.0M in FY 2023 to $370.5M in FY 2025 while net margin is 0% and the whale 13F flow pillar scored only 4 of 20.. With a beta of 1.0 and the stock sitting at $13.22 (52-wk range $12.72–$16.67), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%